Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Net Margin (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Net Margin for 9 consecutive years, with 8.16% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Net Margin fell 261.0% year-over-year to 8.16%, compared with a TTM value of 6.25% through Dec 2025, down 88.0%, and an annual FY2025 reading of 44.39%, up 4978.0% over the prior year.
  • Net Margin was 8.16% for Q2 2025 at VYNE Therapeutics, down from 3.96% in the prior quarter.
  • Across five years, Net Margin topped out at 7507.87% in Q1 2022 and bottomed at 7465.52% in Q4 2022.
  • Average Net Margin over 5 years is 859.41%, with a median of 48.68% recorded in 2023.
  • The sharpest move saw Net Margin soared 1171395bps in 2022, then tumbled -751797bps in 2023.
  • Year by year, Net Margin stood at 1171.43% in 2021, then plummeted by -537bps to 7465.52% in 2022, then skyrocketed by 99bps to 48.68% in 2023, then skyrocketed by 80bps to 9.52% in 2024, then grew by 14bps to 8.16% in 2025.
  • Business Quant data shows Net Margin for VYNE at 8.16% in Q2 2025, 3.96% in Q1 2025, and 9.52% in Q4 2024.